Among the three classic Philadelphia chromosome-negative myeloproliferative neoplasms, primary myelofibrosis (PMF) is the most severe in terms of disease biology, survival and quality of life. Abnormalities in the process of differentiation of PMF megakaryocytes (MKs) are a hallmark of the disease. Nevertheless, the molecular events that lead to aberrant megakaryocytopoiesis have yet to be clarified. Protein kinase Cε (PKCε) is a novel serine/threonine kinase that is overexpressed in a variety of cancers, promoting aggressive phenotype, invasiveness and drug resistance. Our previous findings on the role of PKCε in normal (erythroid and megakaryocytic commitment) and malignant (acute myeloid leukemia) hematopoiesis prompted us to investigate whether it could be involved in the pathogenesis of PMF MK-impaired differentiation. We demonstrate that PMF megakaryocytic cultures express higher levels of PKCε than healthy donors, which correlate with higher disease burden but not with JAK2V617F mutation. Inhibition of PKCε function (by a negative regulator of PKCε translocation) or translation (by target small hairpin RNA) leads to reduction in PMF cell growth, restoration of PMF MK differentiation and inhibition of PKCε-related anti-apoptotic signaling (Bcl-xL). Our data suggest that targeting PKCε directly affects the PMF neoplastic clone and represent a proof-of-concept for PKCε inhibition as a novel therapeutic strategy in PMF.
INTRODUCTION
Philadelphia chromosome-negative myeloproliferative neoplasms (Ph neg MPNs) are clonal hematopoietic disorders including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). 1 MF, either primary MF (PMF) or arising from a previous PV or ET, is the most severe in terms of survival and quality of life, and is typified by debilitating constitutional symptoms, anemia, thrombocytopenia or thrombocytosis, progressive bone marrow (BM) fibrosis and high risk of leukemic transformation. 2 The molecular bases of Ph neg MPNs are extremely complex. A first insight has been provided in 2005 by the landmark discovery of the JAK2V617F mutation (~96% of PVs and 50%-60% of ETs and MFs), [3] [4] [5] followed by JAK2 exon 12 mutations (1%-3% of PVs) 6 and thrombopoietin (TPO) receptor (MPL) mutations (5%-10% of ETs and MFs) [7] [8] [9] , all leading to increased Janus kinase 2 (JAK2)-signal transducer and activator of transcription (STAT) signaling. Since then, many other mutations have been described (namely TET2, 10 IDH1/2, 11 ASXL1, 12 EZH2, 13 DNMT3A, 14 IKZF1, 15 CBL, 16 SH2B3 (ref. 17) and, very recently, CALR 18, 19 ) which, although contributing to the neoplastic process, lack disease specificity and, in most of the cases, affect only a minority of MPN patients. 20, 21 Although the pathobiology of Ph neg MPNs still remains controversial, aberrant megakaryocytopoiesis is a distinctive and clinically relevant feature. 22 In MF, specifically, BM megakaryocytes (MKs) are markedly hyperplastic, display peculiar morphological abnormalities such as tight clustering, smaller size and hypolobulated nuclei, 23 and have a predominant role in BM fibrotic changes. 24 Ciurea et al. 25 demonstrated that MKs generated in vitro from PMF CD34 + cells recapitulate the same atypia of PMF MKs in vivo, such as smaller dimensions, reduced ploidy and increased proliferative capacity associated with a decreased rate of apoptosis, likely due to Bcl-xL overexpression.
More recently, Balduini et al. 26 showed that PMF MKs display impaired in-vitro proplatelet formation when compared with MKs derived from ET, PV and healthy subjects.
Collectively, this data suggests that PMF MKs show enhanced proliferation and impaired differentiation both in vivo and in vitro.
Protein kinase Cε (PKCε) is a calcium-independent, phorbol ester/diacylglycerol-sensitive serine/threonine kinase. Phosphorylation at three distinct sites in the catalytic kinase core is required for the enzyme to bind to, and be activated by, lipid-derived second messengers. 27, 28 On activation, PKCε translocates from the cytosol to the particulate cell fraction via interaction with its anchoring proteins εRACKs (receptors for activated C kinase), which provide access to PKCε substrates. 29, 30 Consequently, the interaction between PKCε and εRACK is a required step for PKCε function. 31, 32 PKCε modulates a variety of cellular functions including cell adhesion and motility, proliferation, differentiation and survival. 27 Emerging data now point to PKCε as the one displaying the greatest oncogenic potential among different PKC family isoforms. 33, 34 PKCε is overexpressed in a variety of both solid and hematologic malignancies, such as colon, 35 breast, 36 stomach, 37 prostate, 38,39 thyroid 40 and lung cancers, 41 aggressive gliomas, 42 hairy cell leukemias 43 and acute myeloid leukemias. 44 PKCε also has a crucial role in the production and function of human red blood cells and platelets, in both normal and pathologic conditions. 45 We have demonstrated that PKCε levels peak at day 6 of culture and then progressively decrease during in-vitro megakaryocytic differentiation of normal CD34 + cells. PKCε downmodulation is necessary for MK full maturation, as a forced expression of PKCε from day 8 onward prevents MK full differentiation via Bcl-xL overexpression. 46 During malignant hematopoiesis, we have demonstrated that PKCε is overexpressed in acute myeloid leukemia blasts, and that its downmodulation sensitizes acute myeloid leukemia cells to TRAIL (TNF-related apoptosis-inducing ligand)-mediated apoptosis and induces their full differentiation along the MK lineage. 44 As the role of PKCε in Ph neg MPNs has not been investigated, we evaluated its potential involvement in the molecular pathophysiology of PMF aberrant megakaryocytopoiesis.
SUBJECTS AND METHODS Subjects
This study was approved by the Ethical Committee of Parma University Hospital. After written informed consent,~30 ml of peripheral blood from 15 PMF patients were collected in ethylenediaminetetraacetic acid tubes. Diagnosis was established according to the World Health Organization 2008 criteria. 47 Leukoapheresis bags from 10 granulocyte colonysimulating factor-mobilized donors were used as controls (healthy donors, HDs).
PMF patients' samples were collected at the time of diagnosis (codes 1-5, 8-9, 11, 12, 14 and 15) or after cytoreductive treatment washout (codes 6-7, 10 and 13).
Patient data were retrospectively collected from clinical charts. Prognostic risk category was assessed according to the International Prognostic Scoring System (IPSS) 48 for newly diagnosed patients or according to the dynamic IPSS (DIPSS) 49 for patients with ongoing disease at the time of sample collection. Complete clinical information were available for 13 out of 15 PMFs, as detailed in Table 1 .
Cell cultures
Human erythroleukemia cell line (HEL) was grown in 10% fetal bovine serum-enriched RPMI medium at the optimal density of 0.5 × 10 6 cells/ml. Mononuclear cells from PMFs and HDs were obtained by Ficoll gradient. Primary CD34 + cells were isolated by immunomagnetic positive selection as described. 46 Only samples exceeding 95% purity were used for subsequent experiments. Purified CD34 + cells were cultured up to 14 days, at an optimal cell density of 1 × 10 6 /ml, in serum-free X-vivo medium supplemented with 3 ng/ml interleukin-3 (only day 0), 200 ng/ml TPO and 50 ng/ml stem cell factor renewed every 72 h (PeproTech, London, UK). Cell number and viability were determined by Trypan Blue staining. Fold increase (FI) was calculated with respect to the number of CD34 + cells plated at day 0. At day 6, 9, 11 and 14, cells were collected for further analyses.
MK isolation
At day 11 of culture, CD61 + cells were isolated using the CD61 + Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's recommendations. A purity ⩾ 90% was verified flow cytometrically and cell lysates were subjected to western blot analyses.
Assessment of MK differentiation
Cell diameter was assessed by ImageJ software (National Institutes of Health, Bethesda, MD, USA) analyzing 100 cells per representative highpower field images (Leica IM DL (Leica Camera, Wetzlar, Germany) magnification × 40/0.5 numerical aperture). Morphology was analyzed by light microscopy (May-Grünwald Giemsa staining). Proplatelet formation was evaluated by immunofluorescence as previously described 50 (see also Supplementary Data) and was quantified by assessing the number of proplatelet-forming MKs/100 cells per representative high-power field images obtained by Leica IM DL (magnification × 40/0.5 numerical aperture). All analyses were performed at day 14 of culture.
Flow cytometric analyses
Aliquots of 0.1 × 10 5 cells were labeled with CD34-RPE before and after selection at day 0, to check purity. To assess megakaryocytic differentiation, aliquots of 0.2 × 10 5 cells from day-14 cultures were labeled with RPE-conjugated anti-CD61, anti-CD41, anti-Glycophorin-A, anti-CD34 and anti-CD33; RPE-Cy5-conjugated anti-CD42b; and fluorescein isothiocyanate-conjugated anti-CD14 and anti-CD15, as described. 46 Expression of CD61 was performed at day 11 as well, before and after CD61 + cell selection, to check purity.
For ploidy analysis, aliquots of cells were permealized with 70% ethanol overnight at 4°C, washed with phosphate-buffered saline and incubated in phosphate-buffered saline containing 50 μg/ml propidium iodide and 100 μg/ml RNAse-A (Sigma-Aldrich, St Louis, MO, USA) for 15' in dark at room temperature before analysis. PMF and HD cultures were infected at day 5 of megakaryocytic differentiation and cells were subsequently cultured with TPO and stem cell factor in the presence of puromycin, to select infected, puromycinresistant cells. HEL cells were collected for protein expression analysis after 5 days of puromycin selection.
Pharmacological inhibition of PKCε activity
PKCε activity was inhibited by the εV1-2 peptide (AnaSpec, Inc., Fremont, CA, USA), which blocks PKCε-εRACK interaction and is delivered into cells by a cargo peptide (TAT [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ); efficacy and specificity of this compound have already been tested previously. [51] [52] [53] From day 3, PMF cultures (n. 3) were treated with the εV1-2 peptide (1 μM, renewed every 48 h) or with the same concentration of sole εV1-2 delivery peptide (TAT [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] as control. Untreated cultures were used for comparison.
Western blotting
Fifty micrograms of proteins were separated on 10% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and incubated with anti-PKCε, anti-Bcl-xL, anti-JAK2, anti-phospho-JAK2, anti-STAT5, anti-phospho-STAT5 and anti-glyceraldehyde 3-phosphate dehydrogenase antibodies (see Supplementary Data).
Statistical analysis was performed by t-test or using analysis of variance and Dunnett's test or Tukey's test, when applicable.
RESULTS

PMF CD34 + cells show in-vitro enhanced proliferation and impaired megakaryocytic differentiation
To evaluate proliferation and megakaryocytic differentiation of primary CD34 + cells from PMFs and HDs, cells from each conditions were grown in serum-free cultures. Purity of immunomagnetically isolated cells was checked after selection (Supplementary Figure S1a ) and a multi-parametric characterization of cell population at the end of both PMF and HD cultures was performed. As shown in Supplementary Figures S1b and c, only MK-committed cells could be detected.
Changes in cell growth were assessed as the FI in cell numbers from days 0 to 14. As expected, PMF CD34 + cells showed a significantly higher expansion capacity at each time point of the culture analyzed (day 3, 6, 9, 11 and 14) ( Figure 1a ). Indeed, at the end of the culture (day 14), PMF CD34 + cells displayed a 12.7 FI in cell expansion compared with HD CD34 + cells (38.3 ± 17.2 vs 2.7 ± 2.9, P = 0.006).
The differentiation state of PMF and HD megakaryocytic cultures was assessed at day 14 by cell size (Figure 1b ), surface antigen expression ( Figure 1c and Supplementary Figures S1b and c), ploidy, cell morphology ( Figure 1d ) and proplatelet generation (Figure 1e and Supplementary Figure 4a ).
At the end of cultures, analysis of cell distribution (indicated as %) according to the diameter revealed that~60% PMF cells have a diameter ranging from 8 to 9.9 μm, whereas more than 80% of HD cells have a diameter ⩾ 10 μm, with~40% within a range of 10 and 11.9 μm, and~15% exceeding 14 μm (Po0.001) ( Figure 1b ). As shown in Supplementary Figure S1d , differences in cell size between PMF and HD cultures correlate with the phenotype.
Day-14 MK maturation was also evaluated by flow cytometric expression of early (CD41) and late (CD42b) MK surface antigens (Figure 1c and Supplementary Figures S1b and c) . Compared with HDs, PMF specimens displayed significantly lower percentages of CD41 + (PMF = 25.7 ± 18.2% vs HD = 65.9 ± 19.4%, P = 0.04), CD42b + (PMF = 16.2 ± 17.5% vs HD = 53.3 ± 19.7%, P = 0.04) and CD41 + /CD42b + cells (21.9 ± 11.6% vs 62.5 ± 6.9%, P o0.001).
Ploidy and morphological analysis after May-Grünwald Giemsa staining of a representative PMF vs HD megakaryocytic culture at day 14 showed a lower DNA content in the PMF sample (23.9% vs 36.5% of HD, Figure 1d ), and smaller size and nuclear hypolobulation of PMF MKs compared with the larger, multilobulated HD MKs (Figure 1d , inserts).
Finally, PMF megakaryocytic cultures showed significantly impaired proplatelet generation compared with HDs, as indicated by immunofluorescence studies (Figure 1e , I-II) and proplatelet formation assays (PMF = 1.16 ± 0.64 vs HDs = 4.81 ± 1.39, P = 0.003, Supplementary Figure S4a ).
Collectively, these data provide a comprehensive characterization of in-vitro behavior of TPO-stimulated PMF CD34 + cells in our serum-free-based culture system, showing enhanced growth and impaired MK differentiation compared with CD34 + cells derived from HDs.
PMF MK cultures display higher levels of PKCε and Bcl-xL
We previously demonstrated that the expression of PKCε and, concurrently, of Bcl-xL changes throughout the course of in-vitro MK differentiation of primary human CD34 + cells, peaking at day 6 and then progressively decreasing till nearly undetectable levels at day 14 of culture. Therefore, we evaluated the expression levels of PKCε and Bcl-xL proteins during in-vitro MK differentiation of primary CD34 + cells from PMF and HD in the unfractioned cell population (Figures 2a and b ) and, at the end of the culture, in PMF and HD CD61 + cells ( Figure 1c ).
We found that PKCε and Bcl-xL levels are significantly higher in PMF megakaryocytic cultures compared with HDs at each time point analyzed, and that the two proteins are modulated with a similar kinetic during megakaryocytic differentiation (Figures 2a and b) .
We then focused on the expression of PKCε and Bcl-xL in more differentiated cells at the end of the culture, comparing PKCε and Bcl-xL protein levels in day 11-CD61 + cells immunomagnetically selected from PMF and HD cultures. Similar to what was observed in the unfractioned cell population, PMF CD61 + cells retained higher levels of PKCε and Bcl-xL compared with HD CD61 + cells (Figure 2c ).
PKCε downmodulation does not affect the activation status of JAK/STAT signaling To investigate a potential correlation between PKCε signaling and JAK/STAT axis, we tested the effects of shRNA-mediated downregulation of PKCε expression on HEL cells and we found that PKCε silencing does not cause any statistically significant modulation of total and phosphorylated JAK2 and STAT5 (Supplementary Figure S2 25 In addition, high-risk patients revealed impaired megakaryocytic differentiation potential, as indicated by the lower % of CD41 + , CD42b + and CD41 + /CD42b + cells (26.3 ± 9.4 vs 54.2.6, P = 0.008; 16.1 ± 8 vs 38.2 ± 3, P = 0.011; 14.2 ± 7.5% vs 34 ± 4.4% P = 0.017, respectively; Figure 3c ) and proplatelet-forming MKs (0.67 ± 0.21 vs 1.8 ± 0.25 P = 0.004, Figure 3e ). We did not observe any significant differences by stratifying patients according to JAK2 mutational status (for CD41 + : 49.4 ± 10.8% of JAK2V617F neg vs 31.2 ± 17.8 of JAK2V617F pos PMFs, P = 0.21; for CD42b + : 32.8 ± 6.7% of JAK2V617F neg vs 21.5 ± 17.2% of JAK2V617F pos PMFs, P = 0.35; for CD41 + /CD42b + : 29.3 ± 6.6% of JAK2V617F neg vs 19 ± 15.7 of JAK2V617F pos PMFs, P = 0.35 (Figure 3d) ; for proplatelet-forming MKs: 1.36 ± 0.73% for JAK2V617F neg vs 1.22 ± 0.65% for JAK2V617F pos PMFs, P = 0.82 (Figure 3f) ).
Finally, we found that megakaryocytic cultures from high-risk patients are characterized by higher expression of PKCε (indicated as relative PKCε/glyceraldehyde 3-phosphate dehydrogenase optical density values) as compared with low/intermediate risk patients (1.75 ± 0.52 vs 0.82 ± 0.29, P = 0.023; Figure 3g ), whereas PKCε levels are comparable among JAK2V617F pos and JAK2V617F neg patients (1.11 ± 0.34 vs 1.3 ± 0.8, P = 0.72; Figure 3h ).
PKCε downregulation with specific shRNA restores PMF MK morphology and proplatelet formation
To determine whether PKCε functionally contributed to the impaired MK growth and differentiation abnormalities in PMF, we tested the effects of shRNA-mediated downregulation of PKCε expression (shPKCε) on PMF megakaryocytic maturation.
As shown in Figure 4a , PKCε downregulation with specific shRNA induced a right shift in cell distribution according to the diameter. Approximately 50% of the cells (46.5 ± 2.1%) had a diameter ranging from 10 to 11.9 μm vs 39.0 ± 0% of PMF untreated (UNTR) (P = 0.03) and 26.5 ± 10.6% of PMF control shRNA (shCT) (P = 0.03). Moreover, 6.5 ± 0.7% of PMF shPKCε cells exceed 14 μm of diameter vs 0% of PMF UNTR and PMF shCT (P o 0.001).
In addition to a significant increase in cell size, shPKCε restored morphologically mature MKs (as shown by the multinucleated forms in Figure 4b , II), capable to elongate proplatelets (Figure 4c Figure S4b ).
To further support our findings, we verified whether PKCε silencing could accelerate MK differentiation of normal CD34 + cells and we found that inhibition of PKCε translation by specific shRNA from day 5 onward in HD cultures led to up to~80% of increase in CD41 + cell output (Supplementary Figure S3) .
Collectively, these data demonstrated that downregulation of PKCε in the later phase of megakaryocytopoiesis is critical for adequate MK maturation; if this does not happen as in the case of PMF, its inhibition by specific shRNA allows PMF MK terminal differentiation into mature, proplatelet-generating forms.
PKCε pharmacological inhibition reduces cell growth and restores megakaryocytic differentiation of PMF CD34 + cells Given these data, we sought to assess whether PKCε pharmacological inhibition was able to affect in-vitro growth and megakaryocytic differentiation of primary PMF CD34 + cells. To test this, PKCε activity was specifically inhibited by a commercially available compound, the εV1-2 peptide.
We first observed that PKCε inhibition led to up to~20% of reduction of PMF CD34 + cell growth capacity (assessed as residual FI after the addition, from day 3 onward, of εV1-2), whereas the sole TAT 47-57 did not produce any effect on cell growth (Figure 5a ), indicating that PKCε inhibition significantly reduced PMF CD34 + cell expansion capacity.
We then tested the effects of PKCε inhibition on PMF CD34 + megakaryocytic differentiation, assessed by cell dimension (Figure 5b) , expression of megakaryocytic differentiation antigens (Figure 5c ), ploidy and morphology (Figure 5d ), and proplatelet formation (Figure 5e and Supplementary Figure S4c) .
First, treatment with the εV1-2 peptide also induced a right shift in cell distribution expressed as percentage of cells with a given range diameter, in analogy to what we observed with shRNA ( Figure 4a ). In fact, in PMF+εV1-2 cultures, 48.7 ± 3.2% of the cells display a diameter between 10 and 11.9 μm as compared with 25.7 ± 9.3% of PMF UNTR and with 19.7 ± 8% of PMF+TAT (P = 0.006). Moreover,~10% of the cells exceed 14 μm of diameter as compared with 0% of PMF UNTR and PMF+TAT (P = 0.013) (Figure 5b ). This distribution of PMF+εV1-2 cultures exactly overlaps the one described for HDs (see Figure 1b ).
In addition, we found that PKCε inhibition induced the generation of mature MKs: CD42b + and CD41 + /CD42b + cell populations increased by 430% (P o0.01, Figure 5c , data expressed as % of untreated cultures). No statistically significant increase of CD42b + and CD41 + /CD42b + cells was produced by TAT [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . PKCε inhibition led only to a slight increase of CD41 + cells (Figure 5c ), which is not surprising, as CD41 is an early differentiation marker.
Morphology of MKs generated from the εV1-2-treated cultures mirrors the more mature phenotype with respect to control cultures, as demonstrated by the increment in DNA content (see ploidy analysis: 35.5% vs 24.3% of PMF UNTR and 22.3% of PMF TAT, Figure 5d ) and by their abundant cytoplasm and multilobulated nuclei (Figure 5d, inserts) .
Immunofluorescence studies reveal that MKs from the εV1-2treated cultures are capable of undergoing cytoskeleton modifications and generate proplatelets when compared with the PMF UNTR and PMF+TAT (Figure 5e , I-III) conditions. Moreover, the number of proplatelet-forming MKs in εV1-2-treated cultures is threefold higher than in PMF UNTR and PMF+TAT conditions ( Supplementary Figures S4C, P = 0 .006, data are expressed as % of untreated cultures). Overall, these data suggest that PKCε pharmacological inhibition hampers PMF cell growth and promotes restoration of PMF MK morphology, phenotype and ability to generate proplatelets, all relevant parameters of MK terminal differentiation.
PKCε inhibition reduces the levels of the anti-apoptotic proteins Bcl-xL in PMF MK cultures
In order to demonstrate that PKCε inhibition was capable to switch off the downstream anti-apoptotic signaling that contributed to PMF cell enhanced proliferation, we tested whether PMF MKs generated from εV1-2and shPKCε-treated cultures had reduced levels of the anti-apoptotic protein Bcl-xL.
We found that both inhibition of PKCε function (by the εV1-2 peptide, Figure 6a ) and translation (by target shRNA, Figure 6b ) leads to a statistically significant decrease (~30%) in the amount of Bcl-xL protein (P = 0.025 and P = 0.049, respectively; data are expressed as relative Bcl-xL/glyceraldehyde 3-phosphate dehydrogenase optical density values and are presented as % of untreated cultures).
DISCUSSION
Hyperplasia of morphologically abnormal MKs, overproduction of pro-inflammatory cytokines, BM fibrosis and consequent extramedullary hematopoiesis are hallmarks of PMF.
The molecular events that lead to enhanced growth and impaired megakaryocytic differentiation of PMF CD34 + cells are still largely unknown. In the present study, we aimed to unravel one of the potential mechanisms that accounts for this pathognomonic aspect, identifying the ε isoform of novel PKCs as a crucial factor in this process. PKCε is finely modulated in in-vitro models of human megakaryocytopoiesis, reaching the highest levels in early MK progenitors and then decreasing in more differentiated MKs. As a forced expression of PKCε in the later phases of megakaryocytopoiesis interferes with MK maturation, 46 while its downregulation accelerates the process of differentiation, we hypothesized that PKCε overexpression could underlie PMF MK-altered differentiation and tested whether its modulation could affect PMF MK maturation.
First, we assessed the megakaryocytic commitment of PMF CD34 + cells in our serum-free-based culture system and, consistently with previous findings, we observed that, with respect to normal CD34 + cells, PMF CD34 + cells display increased proliferative capacity associated with impaired megakaryocytic differentiation assessed by a complete multi-parametric analysis represented by: morphology (dysplastic), cell size (small), expression of megakaryocytic surface markers (reduced) and proplatelet formation (markedly impaired/absent).
In addition, as we observed some degree of heterogeneity in terms of cell growth and megakaryocytic differentiation among different PMF donors-that could reasonably reflect the broad clinical phenotype of the disease-we investigated a potential correlation between clinical (that is, IPSS/DIPSS risk category) or biological (that is, JAK2 mutational status) variables and the in-vitro behavior of PMF hematopoietic progenitors, proving that enhanced expansion capacity and impaired megakaryocytic commitment of PMF CD34 + cells are associated with a high IPSS/DIPSS risk category of the donors. No correlation was found with the JAK2V617F mutational status and the observation that PKCε downmodulation does not produce any effect on JAK/STAT signaling in HEL cell model further support the hypothesis that PKCε and JAK/STAT are independent signaling pathways. We then found that for each time point analyzed, PMF CD34 + MK cultures were characterized by significantly higher levels of PKCε and Bcl-xL. In particular, at day 11, when the kinase is supposed to be downmodulated, relative PKCε protein levels are as high as day 6 HDs (0.77 ± 0.4 vs 0.78 ± 0.21, respectively), driving a Bcl-xL-mediated pro-survival and anti-differentiation signal.
We demonstrated that the overexpression of PKCε and Bcl-xL in the late phases of megakaryocytic differentiation (day 11) is attributable to the fact that PMF-CD61 + cells, differently from HD CD61 + cells, retain high expression levels of both proteins. Consequently, we can assume that the overexpression of PKCε and Bcl-xL in PMF MKs has a significant role in the pathophysiology of their aberrant phenotype and behavior.
In addition, we found that PKCε levels are significantly greater in high-vs low-/intermediate-risk patients, whereas no correlation was established according to JAK2 mutational status, indicating that PKCε expression correlates with high IPSS/DIPSS risk categories. This leads us to speculate that PKCε can be used as a marker of high disease burden and a more aggressive disease.
To clarify the contribution of PKCε overexpression to the megakaryocytic differentiation defects of PMF samples, the effects of PKCε inhibition were tested on PMF CD34 + MK differentiation in two different sets of functional experiments: (i) downmodulation of PKCε protein translation by specific shRNA and (ii) pharmacological inhibition of PKCε function by the εV1-2 peptide.
In both systems, we found that PKCε inhibition was capable to improve significantly PMF MK maturation, limit their expansion and reduce anti-apoptotic signaling (Bcl-xL). Taken together, our data indicate that PKCε detains a central role in the pathogenesis of the abnormal megaryocytopoiesis that typifies PMF, and that its overexpression may contribute to sustained proliferation and impaired differentiation of the MK neoplastic clone.
Two aspects concerning new advances in the pathobiology of PMF should prompt us to further investigate the role of PKCε in Ph neg MPNs. First, the emerging concept of PMF as an inflammatory disease. Pro-inflammatory cytokines-mainly released by the MK clone-account not only for BM fibrotic changes, but also for patients' symptoms, poor quality of life and disease prognosis. 54, 55 The role of PKCε in inflammation and related conditions is well established (reviewed in ref. 56 ) and its overexpression in PMF is not only consistent with the inflammatory state that characterizes PMF patients, but also suggests that they might benefit from the effects of PKCε inhibition in the clinical setting.
The second aspect concerns the novel molecular markers described in PMF and ET patients, that is, calreticulin. Very recently, the identification of CALR mutations in 70%-84% of JAK2V617F-negative ETs and MFs has provided a new diagnostic and prognostic tool in Ph neg MPNs. 18, 19 CALR encodes for an endoplasmic protein involved in calcium homeostasis and glycoprotein folding whose role MPN pathogenesis is a matter of current researches. Interestingly, PKCs are direct targets of calcium metabolism and few reports demonstrate that calreticulin is a very good substrate in vitro for all PKCs, including the ε isoform. 57, 58 Overall, our research provides a novel insight into the pathogenesis of PMF and, in our opinion, represents a proof-ofconcept for PKCε as a new potential 'druggable' target in this disease, whose current therapeutic options are still scant. Inhibition of PKCε in the clinical setting is not a distant scenario, as εV1-2 peptide-also known as KAI-1678-has already been tested in phase I/II clinical trials on pain treatment, which resulted in well toleration. 59, 60 Given this, therapeutic strategies based on PKCε inhibition may offer the basis for future treatment of PMF.
